Edwards Lifesciences (EW) Liabilities and Shareholders Equity (2009 - 2026)

Edwards Lifesciences' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $13.3 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 2.3% year-over-year to $13.3 billion in Q1 2026; TTM through Mar 2026 was $53.8 billion, a 9.42% increase from a year earlier, with the FY2025 full-year figure at $13.7 billion, up 4.92% from the prior year.
• Liabilities and Shareholders Equity fell to $13.3 billion in Q1 2026 per EW's latest filing, from $13.7 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $13.7 billion in Q4 2025 and bottomed at $8.3 billion in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $9.7 billion (2024), against an average of $10.8 billion.
• Across the five-year window, Liabilities and Shareholders Equity slipped 2.47% in 2022 and surged 39.43% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $8.3 billion in 2022, then gained by 12.91% to $9.4 billion in 2023, then jumped by 39.43% to $13.1 billion in 2024, then grew by 4.92% to $13.7 billion in 2025, then declined by 2.75% to $13.3 billion in 2026.
• Per Business Quant, the three latest EW Liabilities and Shareholders Equity figures stand at $13.3 billion (Q1 2026), $13.7 billion (Q4 2025), and $13.3 billion (Q3 2025).